# A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

> **NCT02282826** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 48 (actual)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **DRUG:** GZ402668
- **DRUG:** placebo
- **DRUG:** GZ402668
- **DRUG:** placebo
- **DRUG:** acyclovir

## Key facts

- **NCT ID:** NCT02282826
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282826, "A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02282826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*